Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Date:11/7/2013

s' equity:  Accounts payable and accrued liabilities$
2,730$
7,050  Current portion of long-term obligations1,0901,084  Warrant liability5483,422  Long term liabilities3,7284,253  Stockholders' equity43,54366,207Total liabilities and stockholders' equity$
,639$
82,016Conference Call Details OncoGenex will host a conference call at 4:30 p.m. Eastern Time today, Thursday, November 7, 2013, to provide a business update and discuss the third quarter 2013 results.

A live event will be available on the Investor Relations section of the OncoGenex website at www.OncoGenex.com. Alternatively, you may access the live conference call by dialing 877-606-1416 (U.S. & Canada) or 707-287-9313 (International). A replay of the webcast will be available approximately two hours after the call and will be archived for 90 days. You can also monitor key information from the conference call by following the new OncoGenex Investor Relations Twitter account at: http://twitter.com/@OncoGenex_IR.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer a
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
3. OncoGenex to Present at Credit Suisse Healthcare Investor Conference
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
7. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
8. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
10. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Polaris Group announced today that the ... 1 trial of ADI-PEG 20 in combination with ... pleural mesothelioma (MPM) and non-squamous non-small cell lung ... ADI-PEG 20, both as monotherapy and in combination ... other indications, including breast cancer, melanomas, ovarian cancer, ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood ... sponsor of the 10th Annual World Stem Cell Summit, the ... stakeholders. The 2014 World Stem Cell Summit will be held ... Antonio, Texas . The World ... development of lifesaving cures and therapies, convening the most prominent ...
(Date:11/18/2014)... Diego, CA (PRWEB) November 17, 2014 Athena ... of Salk , Dr. Beverly Emerson, a professor in the ... of genes. Her most recent discovery points to an “off ... Dr. Emerson’s career and how her local research is making ... will present her findings and then join host Cheryl K. ...
(Date:11/18/2014)... 2014 2014 Deep Research ... professional and in-depth report on Polytetrahydrofuran (PTMEG) ... including its definition, characterization, application, and industry ... exploration covers the worldwide business investigation, including ... covering macroeconomic environment & financial circumstance examination. ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... March 14 Kendle (Nasdaq: KNDL ), ... Senior Vice President and Chief Financial Officer Karl,"Buzz" ... Eleventh,Annual Global Healthcare Conference. The conference will be ... Florida, March 18-20, 2008. Kendle,s,presentation is scheduled for ...
... Diagnostics,Incorporated (NYSE: DGX ), the nation,s leading ... it is scheduled to speak,at the Cowen and ... March 18, 2008, at the Marriott Copley Place, ... begin at,8:45 a.m. Eastern Time., The presentation ...
... March 14 Creighton University,law, science, medical and ... it takes to convert scientific research into new ... a competitive application and,interview process -- are enrolled ... time on Feb. 13. A three-year, $536,000 National ...
Cached Biology Technology:Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference 2Quest Diagnostics to Speak at Cowen and Company 28th Annual Health Care Conference 2NSF Funds New Entrepreneurship Program 2
(Date:11/4/2014)... published research study examining only marketing directed at ... food restaurants has found that the majority of ... to such marketing tactics. , Authored by Arizona ... the study is the first to examine the ... exterior of fast food restaurants and its relationship ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and Markets ... "Cell Therapy - Technologies, Markets and Companies" to their ... therapy technologies and methods, which have already started to play ... cell transplantation is replacing the old fashioned bone marrow transplants. ... therapy is bound to become a part of medical practice. ...
(Date:11/2/2014)... issue of Physics World , James Dacey explores ... of death" to take their innovations from the lab ... gruelling challenge facing all start-up companies as they move ... because of two main factors: physics-based inventions are usually ... turn out to be a lot more complicated than ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3The 'valley of death' facing physics start-ups 2
... Los Baos, Philippines A small insect that has devastated ... over the past few yearscausing the loss of thousands of ... productionis the focus of a critical and timely conference this ... major type of rice pest that can destroy one-fifth of ...
... and Texas A & M University have discovered a ... specific tissues in animals. In studies to determine ... group previously identified a region of a smooth muscle ... of any plasmid carrying this sequence uniquely in cultured ...
... to Consultancy in Automotive, IRVINE, Calif., June 20 ... auto industry executive who has worked with,Jaguar, Audi, Volkswagen, ... The,position will be based in Irvine, Calif., and will ... responsible for managing existing,client relationships as well as developing ...
Cached Biology News:Research required urgently to control planthopper pests 2Research required urgently to control planthopper pests 3New paradigm for cell-specific gene delivery 2Len Hunt Joins Gallup Consulting Group 2
...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Assay Diluent, 10 L...
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
Biology Products: